European Union regulatory agency has started reviewing Russian coronavirus vaccine Sputnik V

The European Medicines Agency (EMA) on Thursday began a process of “continuous review”, a real-time analysis, of data on the safety, effectiveness and quality of the Russian vaccine against the covid-19 Sputnik-V, the process which could lead to the authorization for the use of this medicine in the European Union (EU).

It’s a statement, the European regulator stressed that the decision to take the plunge “is based on the results of laboratory studies and clinical studies in adults” that the developer of the drug shared with European scientists at the EMA, information already analyzed by its experts at its headquarters in Amsterdam.

For their part, coinciding with the announcement of the EMA, the Russian authorities have declared themselves ready to provide vaccines to 50 million Europeans from June,

“Following the approval of the EMA, we would be able to provide vaccines to 50 million Europeans from June 2021”said in a press release Kirill Dmitriyev, director of the Russian sovereign wealth fund, which contributed to the development of the Sputnik V vaccine.

“Sputnik V can make an important contribution to save millions of lives in Europe”, dijo Dmitriyev.

“Those who work together on vaccines should put politics aside. The cooperation with the EMA is the perfect example that joining forces is the only way to end the pandemic ”, he added, stressing that the injectable has already been approved by around 40 countries.

In recent weeks there has been a round-trip statements from those responsible for the Russian vaccine, who claimed to have sent all the information for the drug to be approved by the EMA, and the European regulatory body, which claimed to have received nothing.

Russian vaccine met with skepticism by western countries but convince the experts, especially after the publication of the results in the scientific journal The Lancet, according to which, Sputnik V will be effective in 91.6% of cases symptomatic of covid-19.

KEEP READING: